InvestWithTheBeast Posted - 2 days ago

$IGC 5000 locked and loaded for 2+ in the near future

Lilrahrah Posted - 2 days ago

$IGC just threw $500 as a lotto play it looks pretty good for a run !!

EyeingTheDips Posted - 12/31/24

$IGC IGC-AD1 Clinical Trial Progress: In November 2024, IGC Pharma announced additional interim results from its ongoing Phase 2 clinical trial of IGC-AD1, a treatment for agitation in Alzheimer's patients. The interim data indicated cognitive improvements in the active treatment group compared to placebo, with no serious adverse events or deaths reported. Expansion into Metabolic Disorders: In August 2024, the company expanded its drug portfolio to include IGC-1A, a potential new GLP-1 agonist targeting metabolic disorders. This strategic move aims to diversify their therapeutic offerings and address a broader range of health conditions.

Tedzz Posted - 12/31/24

$IGC garbage needs to rip or go to .10

EyeingTheDips Posted - 12/27/24

$IGC Price Targets: Analysts have set 12-month price targets ranging from $3.50 to $4.00, with an average target of $3.75. This suggests a potential increase of approximately 914% from the current stock price. Ratings: The consensus among analysts is a "Strong Buy," indicating optimism about the company's future performance.

Tedzz Posted - 12/26/24

$STEM should baught this instead of $IGC 🤣🤣

Tedzz Posted - 12/26/24

$IGC huge wall at .3735

EyeingTheDips Posted - 12/25/24

$IGC Looking ahead, IGC Pharma plans to initiate new trials focused on IGC-AD1's potential to modify amyloid plaque progression, with the goal of delivering breakthrough treatments in Alzheimer's disease and driving substantial value for shareholders.

EyeingTheDips Posted - 12/25/24

$IGC IGC-1C: This small-molecule modulator targets tau protein phase separation, addressing a major disease pathway in Alzheimer's. Preclinical results have been promising, strengthening IGC Pharma's Alzheimer's portfolio. Financially, IGC Pharma reported a 42% increase in revenue for the second quarter of fiscal 2025, driven by growth in its Life Science Segment. The company continues to invest in research and development, with a focus on advancing its clinical trials and preclinical research.

EyeingTheDips Posted - 12/25/24

$IGC TGR-63: Preclinical analyses have demonstrated that TGR-63 can cross the blood-brain barrier with a favorable safety profile, positioning it for further exploration as a treatment for Alzheimer's disease. IGC-1A: Identified through AI modeling as a potential GLP-1 agonist, IGC-1A opens new avenues in metabolic and neurological treatments, enhancing IGC Pharma's competitive edge and expanding market opportunities.

EyeingTheDips Posted - 12/25/24

$IGC IGC Pharma is actively advancing its portfolio of treatments targeting Alzheimer's disease and related disorders. Key developments include: IGC-AD1: This cannabinoid-based formulation is currently in a Phase 2 clinical trial aimed at treating agitation in Alzheimer's dementia. Recent interim results have highlighted cognitive benefits, suggesting potential as a disease-modifying therapy addressing both amyloid-beta plaques and tau pathology.

PhillFosters Posted - 12/24/24

$IGC Bought about 450 in for an average of .37 and I will be adding as the stock scales down. Looking to hold for a few months to try to ride the yearly run this stock always does near the summertime. Been a flipper of this stock almost every year, good luck everyone! Hopefully it runs to 4$ like a few summers ago. Realistically looking to start taking profit at the 1$ mark and riding out the profit further if possible. Good luck traders!

EyeingTheDips Posted - 12/24/24

$IGC With any new partnerships, especially those with international companies, they might start planning for market expansion, particularly in regions where their partners have a strong presence.

EyeingTheDips Posted - 12/24/24

$IGC They could enhance their investor relations efforts, providing detailed briefings or webinars for investors to update them on the outcomes of the conference and future plans.

EyeingTheDips Posted - 12/24/24

$IGC Post-event, IGC Pharma's management might review their corporate strategy, perhaps adjusting their focus on different aspects of their portfolio or reallocating resources based on the outcomes of the partnering event.

EyeingTheDips Posted - 12/24/24

$IGC Depending on the feedback and interest, IGC Pharma might reassess their regulatory strategy, potentially preparing for FDA submissions or seeking regulatory advice to streamline the approval process for their treatments.

EyeingTheDips Posted - 12/24/24

$IGC With the spotlight from the conference, IGC Pharma could focus on advancing their clinical trials, especially for their lead candidate IGC-AD1, which is in a Phase 2 trial for agitation in dementia associated with Alzheimer's. They might also look to expand or speed up these trials based on new funding or partnerships.

EyeingTheDips Posted - 12/24/24

$IGC If there are significant partnerships or funding secured, IGC Pharma might issue press releases or updates to shareholders to inform them of the developments, enhancing transparency, and potentially boosting stock value.

EyeingTheDips Posted - 12/24/24

$IGC Any leads or interest shown during the conference could be pursued, possibly leading to new licensing agreements, R&D collaborations, or funding for their Alzheimer's treatment candidates like IGC-AD1.

EyeingTheDips Posted - 12/24/24

$IGC After making initial contacts at the conference, IGC Pharma would likely schedule follow-up meetings with potential investors or partners to further discuss collaboration opportunities or investment in their projects.

EyeingTheDips Posted - 12/24/24

$IGC IGC Pharma is scheduled to participate in the BioPartnering at JPM event, which is held alongside the J.P. Morgan 43rd Annual Healthcare Conference from January 13-16, 2025. During this event, they plan to meet with investors and partners to discuss their recent achievements and upcoming developments.

EyeingTheDips Posted - 12/23/24

$IGC Analyst forecasts suggest a significant potential upside for IGC's stock. The average 12-month price target is $3.75, with estimates ranging from $3.50 to $4.00. This represents a potential increase of approximately 900% from the current price. The consensus among analysts is a "Strong Buy" rating for IGC Pharma. This indicates a positive outlook on the company's future performance.

EyeingTheDips Posted - 12/23/24

$IGC IGC Pharma has been advancing its Alzheimer's treatment pipeline. Their lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's. Recent interim results have highlighted cognitive benefits of IGC-AD1 for Alzheimer's treatment. For investors, it's noteworthy that IGC Pharma has received a consensus rating of "Buy" from analysts, with a price target of $4.00, indicating a potential upside from the current trading price.

Bulltrader988 Posted - 12/21/24

$IGC "...will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. Event: BIO Partnering @ JPM Date: January 13 – 16, 2025..." https://investor.igcpharma.com/igc-pharma-announces-participation-biopartnering/

Tedzz Posted - 12/20/24

$IGC bullish here 👀👀💪

EyeingTheDips Posted - 12/20/24

$IGC Recently, IGC Pharma announced its participation in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference from January 13 to 16, 2025. During this event, the company's management team will conduct one-on-one meetings with investors and pharmaceutical companies to discuss their business strategy and recent achievements. In addition, Ascendiant Capital Markets recently raised its price target for IGC Pharma from $3.75 to $4.00, maintaining a 'buy' rating on the stock.

RocketQueen Posted - 12/19/24

$IGC should rocket soon.

EyeingTheDips Posted - 12/19/24

$IGC IGC Pharma, Inc., a clinical-stage biotechnology company specializing in Alzheimer's disease treatments, has recently reported its financial results for the second fiscal quarter of 2025, ending September 30, 2024. Revenue and Growth: The company achieved a revenue of approximately $412,000 for the quarter, marking a 42% increase compared to the same period in the previous year. This growth is attributed to the Life Sciences segment, which includes sales of over-the-counter products and private label services. Expenses and Cost Management: Selling, General, and Administrative (SG&A) expenses decreased by 25% to about $1 million, reflecting effective cost management strategies. Research and Development (R&D) expenses were approximately $917,000, a 28% reduction from the prior year, due to cost-efficiency measures while advancing Phase 2 trials of IGC-AD1 and preclinical research on other platforms like TGR-63.

EyeingTheDips Posted - 12/18/24

$IGC 🥱

EyeingTheDips Posted - 12/17/24

@DekmarTrades $RVPH $IGC Thought I'd list two since together they add up to less than $2 a share. #Merry Christmas